Diabetes drug found no better than placebo at treating nonalcoholic fatty liver disease
A diabetes medication described in some studies as an effective treatment for nonalcoholic fatty liver disease (NAFLD) works no better than a placebo, report researchers after conducting the first randomized, double-blind, controlled clinical trial of sitagliptin, an oral antihyperglycemic marketed under the name Januvia. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 12, 2016 Category: Science Source Type: news

Merck to Present Phase 3 Data on Investigational Medicines Ertugliflozin and MK-1293 at the 76th Scientific Sessions of the American Diabetes Association
Dateline City: KENILWORTH, N.J. Additional Analyses from the TECOS Cardiovascular Safety Trial of JANUVIA® (sitagliptin) Also to Be Presented KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that researchers will present data from clinical trials of its investigational diabetes pipeline, JANUVIA® (sitagliptin), and new real-world research in more than 20 scientific data presentations at the ...
Source: Merck.com - Corporate News - May 12, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK ADA Source Type: news

Diabetes drug found no better than placebo at treating NAFLD
A diabetes medication described in some studies as an effective treatment for nonalcoholic fatty liver disease (NAFLD) works no better than a placebo, report researchers at University of California San Diego School of Medicine, after conducting the first randomized, double-blind, controlled clinical trial of sitagliptin, an oral antihyperglycemic marketed by Merck & Co. under the name Januvia. (Source: World Pharma News)
Source: World Pharma News - May 12, 2016 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Diabetes drug found no better than placebo at treating NAFLD
(University of California - San Diego) A diabetes medication described in some studies as an effective treatment for nonalcoholic fatty liver disease (NAFLD) works no better than a placebo, report researchers at University of California San Diego School of Medicine, after conducting the first randomized, double-blind, controlled clinical trial of sitagliptin, an oral antihyperglycemic marketed by Merck & Co. under the name Januvia. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 12, 2016 Category: Global & Universal Source Type: news

Merck sales disappoint as Januvia, Remicade fall short
(Reuters) - Merck & Co Inc on Thursday reported lower-than-expected quarterly revenue, hurt by disappointing sales of its Januvia diabetes treatment and Remicade arthritis drug. (Source: Reuters: Health)
Source: Reuters: Health - May 5, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

Merck posts better-than-expected profit, raises forecast
(Reuters) - Merck & Co Inc reported better-than-expected profit in the first quarter, driven by higher sales of its diabetes drug Januvia and heart drug Zetia. (Source: Reuters: Health)
Source: Reuters: Health - May 5, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

Sitagliptin does not reduce liver fat in NAFLD
BARCELONA – Contrary to expectation, sitagliptin did not reduce liver fat in patients with early diabetes and nonalcoholic fatty liver disease in a double-blind, randomized, placebo-controlled trial.... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - April 30, 2016 Category: Endocrinology Source Type: news

Efficacy of Sitagliptin in Diabetes With High CVD RiskEfficacy of Sitagliptin in Diabetes With High CVD Risk
This study examines the benefits among type 2 diabetes patients at high risk for cardiovascular disease. Cardiovascular Diabetology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 27, 2016 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Gliptin Users Don't Seem to Have Higher CV Risk (CME/CE)
(MedPage Today) -- FDA pilot study contradict earlier results for Onglyza, Januvia (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - April 26, 2016 Category: Endocrinology Source Type: news

Two Diabetes Drugs Don't Pose Higher Heart Failure Hospitalization Risk (FREE)
By Kelly Young Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD The dipeptidyl peptidase-4 (DPP-4) inhibitors saxagliptin and sitagliptin are not associated with increased risk for heart failure hospitalization relative to other diabetes … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - April 25, 2016 Category: Primary Care Source Type: news

No rise in serious HF seen in patients taking saxagliptin or sitagliptin
Neither saxagliptin nor sitagliptin, the two oral DPP-4 inhibitors most commonly used as antihyperglycemic medications, raised the risk of hospitalization for heart failure in a large... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - April 25, 2016 Category: Endocrinology Source Type: news

Diabetes drugs cleared of vascular harm
Two studies suggest that neither sulfonylureas nor sitagliptin increase the risk of adverse cardiovascular outcomes in patients with Type 2 diabetes. (Source: MedWire News)
Source: MedWire News - April 20, 2016 Category: Consumer Health News Tags: Diabetes Source Type: news

Disappointing data for diabetes drug in the treatment of non-alcoholic fatty liver disease
(European Association for the Study of the Liver) New data presented today at The International Liver Congress™ 2016 in Barcelona, Spain, demonstrates that the drug sitagliptin - more commonly used to treat diabetes - was no more effective than placebo for reducing non-alcoholic fatty liver disease. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 16, 2016 Category: Infectious Diseases Source Type: news

Sitagliptin is 'Safest' DPP-4 Inhibitor for Type 2 DiabetesSitagliptin is 'Safest' DPP-4 Inhibitor for Type 2 Diabetes
Detailed assessment of heart-failure outcomes from TECOS study with the type 2 diabetes drug sitagliptin is published and confirms that this DPP-4 inhibitor has the safest cardiovascular profile. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - April 14, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

T2D patients on combination therapy benefit in switch from sitagliptin to liraglutide
BOSTON – Switching from sitagliptin to liraglutide, in combination with metformin, improved control of hypoglycemia and resulted in greater weight loss in patients with type 2 diabetes, reported Dr.... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - April 10, 2016 Category: Endocrinology Source Type: news